Balancing efficacy and safety in the management of atopic dermatitis: The role of methylprednisolone aceponate

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 3, 2011, Pages 251-258

  Luger, T A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

anti inflammatory agents; atopic; corticosteroids; dermatitis; eczema; emollients

Indexed keywords

ANTIINFLAMMATORY AGENT; EMOLLIENT AGENT; METHYLPREDNISOLONE ACEPONATE; PREDNISOLONE;

ATOPIC DERMATITIS; BURNING SENSATION; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRY SKIN; ERYTHEMA; HUMAN; MAINTENANCE THERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; VOLUNTEER;

ANTI-INFLAMMATORY AGENTS; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EMOLLIENTS; HUMANS; METHYLPREDNISOLONE; TREATMENT OUTCOME;

EID: 79751493153     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03789.x     Document Type: Review

References (55)

1. Ross T, Ross G, Varigos G,. Eczema: practical management issues. Aust Fam Physician 2005; 34: 319-324.
2. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006; 61: 969-987. (Pubitemid 44024897)
3. Szczepanowska J, Reich A, Szepietowski JC,. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol 2008; 19: 614-618.
4. Daniels R, Knie U,. Galenics of dermal products-vehicles, properties and drug release. J Deutsch Dermatol Ges 2007; 5: 367-383. (Pubitemid 46648932)
5. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ,. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15.
6. Wiedersberg S, Leopold CS, Guy RH,. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm 2008; 68: 453-466. (Pubitemid 351318206)
7. Brazzini B, Pimpinelli N,. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002; 3: 47-58. (Pubitemid 34158102)
8. Täuber U,. Dermatocorticosteroids: structure, activity, pharmacokinetics. Eur J Dermatol 1994; 4: 419-429. (Pubitemid 24256204)
9. Woźniacka A, Sysa-Jȩdrzejowska A,. Topical steroids-a new approach after 50 years. Med Sci Monit 2001; 7: 539-544. (Pubitemid 32476075)
10. Luger T, Loske K, Elsner P, et al. Topical skin therapy with glucocorticosteroids-therapeutic index. J Deutsch Dermatol Ges 2004; 7: 629-634. (Pubitemid 38931700)
11. Fokkens WJ, Godthelp T, Holm AF, Klein-Jan A,. Local corticosteroid treatment: the effect on cells and cytokines in nasal allergic inflammation. Am J Rhinol 1998; 12: 21-26. (Pubitemid 28160201)
12. Almawi W, Melemedjian O, Rieder M,. An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transplant 1999; 13: 365-374. (Pubitemid 29462185)
13. Nawata H, Okabe T, Yanase T, Nomura M,. Mechanism of action and resistance to glucocorticoid and selective glucocorticoid receptor modulator to overcome glucocorticoid-related adverse effects. Clin Experiment Allergy Rev 2008; 8: 53-56.
14. Haria M, Balfour JA,. Methylprednisolone aceponate. A review of its pharmacological properties and therapeutic potential in the topical treatment of eczema. Clin Immunother 1995; 3: 241-253.
15. Guyre PM, Girard MT, Morganelli PM, Manganiello PD,. Glucocorticoid effects on the production and actions of immune cytokines. J Steroid Biochem 1988; 30: 89-93.
16. Biola A, Pallardy M,. Mode of action of glucocorticoids. Presse Med 2000; 29: 215-223. (Pubitemid 30101709)
17. Falus A, Birõ J, Rákász E,. Cytokine networks and corticosteroid receptors. Ann N Y Acad Sci 1995; 762: 71-77.
18. Valencia IC, Kerdel FA,. Topical corticosteroids. In:, Wolff K, Goldsmith LA, Katz SI, et al., eds. Fitzpatrick's Dermatology in General Medicine, 7th edn. McGraw Hill, New York, NY, 2007: 2102-2106. Chapter 216.
19. Blackwell GJ, Carnuccio R, Di Rosa M, et al. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 1980; 287 (5778): 147-149. (Pubitemid 11227686)
20. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673-684. (Pubitemid 38471336)
21. Kalthoff FS, Chung J, Musser P, Stuetz A,. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003; 133: 350-359. (Pubitemid 37046958)
22. Schwiebert LM, Beck LA, Stellato C, et al. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin Immunol 1996; 97 (1 Pt 2): 143-152. (Pubitemid 26049495)
23. Boschetto P, Rogers DF, Fabbri LM, Barnes PJ,. Corticosteroid inhibition of airway microvascular leakage. Am Rev Respir Dis 1991; 143: 605-609.
24. Haapasaari KM, Risteli J, Koivukangas V, Oikarinen A,. Comparison of the effect of hydrocortisone, hydrocortisone-17-butyrate and betamethasone on collagen synthesis in human skin in vivo. Acta Derm Venereol 1995; 75: 269-271.
25. Lagos BR, Maibach HI,. Frequency of application of topical corticosteroids: an overview. Br J Dermatol 1998; 139: 763-766. (Pubitemid 28520280)
26. Mori M, Pimpinelli N, Giannotti B,. Topical corticosteroid and unwanted local effects. Drug Saf 1994; 10: 406-412.
27. Kao JS, Fluhr JW, Man MQ, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003; 120: 456-464. (Pubitemid 36298433)
28. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allerg Clin Immunol 2009; 123: 1124-1133.
29. Charman CR, Morris AD, Williams HC,. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-936. (Pubitemid 30304603)
30. Lamberts SWJ, Huizenga ATM, de Lange P, et al. Clinical aspects of glucocorticoid sensitivity. Steroids 1996; 61: 157-160. (Pubitemid 26144415)
31. Zentel HJ, Töpert M,. Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate. J Eur Acad Dermatol Venereol 1994; 3 (Suppl 1): S32-S38. (Pubitemid 24152519)
32. Dyes PJ, Marks R,. An appraisal of the methods used in the assessment of atrophy from topical corticosteroids. Br J Dermatol 1979; 101: 599-609. (Pubitemid 10132190)
33. Stenmovic DU,. Corticosteroid-induced atrophy of the skin with telangiectasia: a clinical and experimental study. Br J Dermatol 1972; 87: 548-556.
34. Greaves MW, Gatti S,. The use of glucocorticoids in dermatology. J Dermatol Treat 1999; 10: 83-91. (Pubitemid 29348526)
35. Täuber U,. Pharmacokinetics and 'bioactivation' of MPA. J Eur Acad Dermatol Venereol 1994; 3 (Suppl 1): S23-S31. (Pubitemid 24152518)
36. Zaumseil R-P, Kecskes A, Täuber U, Topert M,. Methylprednisolone aceponate (MPA)-a new therapeutic for eczema: a pharmacological overview. J Dermatol Treat 1992; 3 (Suppl 2): 3-7. (Pubitemid 23016826)
37. Täuber U,. Skin pharmacokinetics of a new topical glucocorticosteroid MPA. In:, Scott RC, et al., eds. Prediction of Percutaneous Penetration, Methods, Measurements, Modelling: Proceedings of a Conference held in April 1989. IBS Technical Services, London, 1990: 37-48.
38. Albrecht G,. Clinical comparison of methylprednisolone aceponate and prednicarbate in chronic eczema. J Eur Acad Dermatol Venereol 1994; 3 (Suppl 1): S42-S48. (Pubitemid 24152521)
39. Mensing H, Lorenz B,. Experience with methylprednisolone aceponate (MPA) in patients suffering from acute and chronic eczema-results of a large observational study. Z Hautkrankh 1998; 73: 281-285.
40. Fritsch P,. Clinical experience with methylprednisolone aceponate (MPA) in eczema. J Dermatol Treat 1992; 3 (Suppl 2): 17-19. (Pubitemid 23016829)
41. Casano AV, Cavallé JR,. The milk formulation in topical corticotherapy: outcomes in children with atopic dermatitis. Monografía de Dermatología 2002; 15: 399-408.
42. Bieber T, Vick K, Fölster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007; 62: 184-189. (Pubitemid 46090301)
43. Sonnichsen N, Zaumseil R-P,. Efficacy and tolerability of methylprednisolone aceponate solution in eczematous diseases of the hairy scalp. Dermatology 1999; 5: 317-324.
44. Peserico A, Städtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008; 158: 801-807. (Pubitemid 351415740)
45. Reitamo S, Allsopp R, Naidoo S,. Treatment of moderate and severe atopic dermatitis in children with twice weekly tacrolimus 0.03% ointment (Abstract P503). J Am Acad Dermatol 2010; 62 (3): AB10.
46. Kecskés A, Heger-Mahn D, Kuhlmann RK, Lange L,. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity. J Am Acad Dermatol 1993; 29: 576-580. (Pubitemid 23289559)
47. Haneke E,. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. J Dermatol Treat 1992; 3 (Suppl 2): 13-15. (Pubitemid 23016828)
48. Rampini E,. Methylprednisolone aceponate (MPA)-use and clinical experience in children. J Dermatol Treat 1992; 3 (Suppl 2): 27-29. (Pubitemid 23016831)
49. Zaumseil R-P, Fuhrmann H, Kecskés A, et al. Methylprednisolone aceponate (Advantan) an effective topical corticoid therapy with few side effects. In:, Macher E, Kolde G, Brucker EB, eds. Jahrbuch der Dermatologie. Biermann-Verlag, Zülpich, Germany, 199293: 247-263.
50. Ortonne J-P,. Safety aspects of topical methylprednisolone aceponate (MPA) treatment. J Dermatol Treat 1992; 3 (Suppl 2): 21-25. (Pubitemid 23016830)
51. Ortonne J-P,. Skin atrophogenic potential of methylprednisolone aceponate (MPA). J Eur Acad Dermatol Venereol 1994; 3 (Suppl 1): S13-S18.
52. Mirshahpanah P, Döcke W-D, Merbold U, et al. Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol 2007; 16: 753-761. (Pubitemid 47261867)
53. Massarano AA, Hollis S, Devlin J, et al. Growth in atopic eczema. Arch Dis Child 1993; 68: 677-679. (Pubitemid 23153255)
54. Alchorne MM, Da CP, Cestari S, et al. A multicenter, comparative, open-labelled, randomized study of tolerability and efficacy of methylprednisolone aceponate and mometasone furoate in children from 2 to 14 years of age suffering from atopic dermatitis. Ped Mod 2003; 39: 275-280.
55. Korotky NG, Taganov AV, Shimanovsky NL,. Use of Advantan in the treatment of atopic dermatitis in children. Pediatriya 2000; 5: 75-78.